source
- FDA issues final guidance on drug-related mobile applicationsThe FDA has released its final guidance addressing software applications that are used in connection with prescription drugs. The guidance clarifies how the agency will evaluate and regulate apps…
- AbbVie’s lutikizumab meets primary endpoint in Phase 3 hidradenitis trial but falls short of market expectationsAbbVie announced that its experimental drug lutikizumab achieved its primary goal in a Phase 3 study of hidradenitis suppurativa, a chronic inflammatory skin disease. The Intrepid trial enrolled a…